Weighing the GLP-1 market

Learn more about how we cultivate and harness world-class intellectual capital and expertise to solve our clients’ most complex challenges.

What We Do

We harness every resource, insight, relationship, and competitive advantage to drive superior results for our clients.

Serving Clients

Analysis and perspectives on the global economy and markets, from across Goldman Sachs

Insights

Our award-winning podcast features Goldman Sachs leaders on the key issues shaping the global economy.

Goldman Sachs Exchanges

We aspire to be the world’s most exceptional financial institution.

Our Firm

We help entrepreneurs create jobs and economic opportunity through rigorous business education programs, access to capital, and networking.

10,000 Small Businesses

There are many chapters in a career. There is only one Goldman Sachs.

Careers

Start with the best. Apply for an eight-to-10 week program for future analysts and associates.

2025 Summer Internship

"Weighing the GLP-1 market"

"The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can or wants to take them. Just how large the addressable market for GLP-1s actually is, and what that means for the drug companies developing them, other exposed industries, and the wider economy, is Top of Mind.\r\n"

The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can or wants to take them. Just how large the addressable market for GLP-1s actually is, and what that means for the drug companies developing them, other exposed industries, and the wider economy, is Top of Mind.

"Goldman Sachs Research"

Goldman Sachs Research

Accessibility Notice:&nbsp;A&nbsp;<a href="/transcript-requests">transcript is available&nbsp;</a>for any video on this page.